Evidence map›Paper›PMID 38788089›Full record

ArticleJournal of Parkinson's disease2024

Immunophenotyping Tracks Motor Progression in Parkinson's Disease Associated with a TH Mutation.

Adithya Gopinath, Adolfo Ramirez-Zamora, Stephen Franks, Tabish Riaz, Aidan Smith, Glen Dizon, Lauryn Hornstein, Jordan Follett, Camille Swartz, Jonathan Bravo and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adithya GopinathDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.
Adolfo Ramirez-ZamoraDepartment of Neurology, University of Florida, Gainesville, FL, USA.
Stephen FranksDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.
Tabish RiazDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.
Aidan SmithDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.
Glen DizonDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.
Lauryn HornsteinDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.
Jordan FollettDepartment of Neurology, University of Florida, Gainesville, FL, USA.
Camille SwartzNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.
Jonathan BravoDepartment of Neurology, University of Florida, Gainesville, FL, USA.
E Lee KugelmannNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.
Matthew FarrerDepartment of Neurology, University of Florida, Gainesville, FL, USA.
Michael S OkunDepartment of Neurology, University of Florida, Gainesville, FL, USA.
Habibeh KhoshboueiDepartment of Neuroscience, University of Florida, Gainesville, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder, with genetic factors accounting for about 15% of cases. There is a significant challenge in tracking disease progression and treatment response, crucial for developing new therapies. Traditional methods like imaging, clinical monitoring, and biomarker analysis have not conclusively tracked disease progression or treatment response in PD. Our previous research indicated that PD patients with increased dopamine transporter (DAT) and tyrosine hydroxylase (TH) in peripheral blood mononuclear cells (PBMCs) might show disease progression and respond to levodopa treatment. Objective: This study evaluates whether DAT- and TH-expressing PBMCs can monitor motor progression in a PD patient with a heterozygous TH mutation. Methods: We conducted a longitudinal follow-up of a 46-year-old female PD patient with a TH mutation, assessing her clinical features over 18 months through DaT scans and PBMC immunophenotyping. This was compared with idiopathic PD patients (130 subjects) and healthy controls (80 age/sex-matched individuals). Results: We found an increase in DAT+ immune cells concurrent with worsening motor scores (UPDRS-III). Following levodopa therapy, unlike idiopathic PD patients, TH+ immune cell levels in this patient remained high even as her motor scores improved. Conclusions: Longitudinal immunophenotyping in this PD patient suggests DAT+ and TH+ PBMCs as potential biomarkers for tracking PD progression and treatment efficacy, supporting further exploration of this approach in PD research.

Indexed as

Disease ProgressionDopamine Plasma Membrane Transport ProteinsImmunophenotypingLeukocytes, MononuclearParkinson DiseaseTyrosine 3-MonooxygenaseFemaleFollow-Up StudiesHumansLongitudinal StudiesMiddle AgedMutationDopamine Plasma Membrane Transport ProteinsTyrosine 3-MonooxygenaseDopamine transporterimmunophenotypeParkinson’s diseasetyrosine hydroxylase

Identifiers

PMID38788089
PMCPMC11191508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.